Research Article
Efavirenz Conceptions and Regimen Management in a Prospective Cohort of Women on Antiretroviral Therapy
Table 1
EFV conceptions and regimen substitutions.
| | EFV conceptions | |
| | Pregnancies carried forward on EFV | 9 (16%) | | Women receiving regimen substitutions | 25 (45%) | | Pregnancies miscarried prior to regimen substitution | 3 (5%) | | Pregnancies terminated | 19 (34%) |
| | Extent of EFV exposure during pregnancy | Median (IQR) |
| | Time from EFV conception to detection , weeks | 4 [1–6] | | Time from pregnancy detection to regimen change , days | 1 [1–28] | | Total time of first trimester EFV exposure in pregnancies carried to term , weeks | 8 [5–13] |
| | Fertility-related regimen substitutions to NVP or LPV/r† | |
| | Clinical characteristics of women changed from EFV to NVP, n = 38 (67%) | Median (IQR) |
| | CD4 count, cells/μL | 257 (185–412) | | Viral load, copies/mL | 1.7 (1.7–2.1) | | Alanine aminotransferase (ALT) levels, U/L | 26 (21–39) |
| | Clinical characteristics of women changed from EFV to Lopinavir/Ritonavir, (33%) | Median (IQR) |
| | CD4 count, cells/μL | 573 (333–684) | | Viral load, copies/mL | 1.7 (1.7-1.7) | | Alanine aminotransferase (ALT) levels, U/L | 25 (19–44) |
|
|
regimen changes for EFV conceptions and preventive changes for women trying to conceive.
EFV: Efavirenz; NVP: Nevirapine; LPV/r: Lopinavir/ritonavir.
|
